Arthritis; Psoriasis flare-up; Baker's cyst ruptured/synovial rupture; This spontaneous case was reported by a consumer and describes the occurrence of SYNOVIAL RUPTURE (Baker's cyst ruptured/synovial rupture), PSORIASIS (Psoriasis flare-up) and ARTHRITIS (Arthritis) in a 51-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product UPADACITINIB (RINVOQ) tablet for Arthropathy psoriatic.    Concomitant products included MAGNESIUM, CYANOCOBALAMIN (VITAMIN B12 [CYANOCOBALAMIN]) and LISINOPRIL for an unknown indication.   On 07-Apr-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 20-Apr-2022, UPADACITINIB (RINVOQ) (Oral) dosage was changed to at an unspecified dose once a day. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. and UPADACITINIB (RINVOQ) (unknown route) at an unspecified dose. On 07-Apr-2022,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced PSORIASIS (Psoriasis flare-up). In April 2022, the patient experienced SYNOVIAL RUPTURE (Baker's cyst ruptured/synovial rupture). On an unknown date, the patient experienced ARTHRITIS (Arthritis). At the time of the report, SYNOVIAL RUPTURE (Baker's cyst ruptured/synovial rupture), PSORIASIS (Psoriasis flare-up) and ARTHRITIS (Arthritis) outcome was unknown.            It was reported that the patient had baker's cyst burst last week in Apr-2022 and baker's cyst was due to arthritis. The patient also had a bad flare after they received Moderna booster on 7-Apr-2022. Reportedly, the therapy start date of Rinvoq was unknown and the patient stopped taking it by 2021 and the patient restarted Rinvoq on 20-Apr-2022 after being off Rinvoq for one year. The patient took RINVOQ (Extended Release) every day before meal, 1 Tablet,1 in 1 Day.  The patient's medical history was not reported.  It was unknown if the patient was enrolled in a COVID-19 Vaccine Trial.  No treatment information was provided. COMPANY COMMENT: This is an spontaneous case concerning a  51-years-old male patient with  medical history of Arthropathy psoriatic treated with UPADACITINIB Concomitant products included MAGNESIUM, CYANOCOBALAMIN (VITAMIN B12 [CYANOCOBALAMIN]) and LISINOPRIL who experienced the unexpected events   of ARTHRITIS (AESI), SYNOVIAL RUPTURE and PSORIASIS  unknown days after  receiving the  3rd  dose of  mRNA-1273 vaccine. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: COMPANY COMMENT: This is an spontaneous case concerning a  51-years-old male patient with  medical history of Arthropathy psoriatic treated with UPADACITINIB Concomitant products included MAGNESIUM, CYANOCOBALAMIN (VITAMIN B12 [CYANOCOBALAMIN]) and LISINOPRIL who experienced the unexpected events   of ARTHRITIS (AESI), SYNOVIAL RUPTURE and PSORIASIS  unknown days after  receiving the  3rd  dose of  mRNA-1273 vaccine. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.